vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Massimo Group (MAMO). Click either name above to swap in a different company.
Massimo Group is the larger business by last-quarter revenue ($21.0M vs $18.7M, roughly 1.1× CytomX Therapeutics, Inc.). Massimo Group runs the higher net margin — 9.5% vs -0.8%, a 10.3% gap on every dollar of revenue. On growth, Massimo Group posted the faster year-over-year revenue change (15.7% vs -25.7%). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -16.5%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Massimo Dutti, S.A. is a Spanish premium clothing retailer specializing in cashmere and wool products, established in 1985 and owned by Spanish multinational company Inditex, the parent company of Zara, Pull&Bear, and other brands.
CTMX vs MAMO — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $21.0M |
| Net Profit | $-154.0K | $2.0M |
| Gross Margin | — | 41.5% |
| Operating Margin | -6.9% | 13.1% |
| Net Margin | -0.8% | 9.5% |
| Revenue YoY | -25.7% | 15.7% |
| Net Profit YoY | 97.6% | 215.0% |
| EPS (diluted) | — | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $21.0M | ||
| Q3 25 | — | $17.0M | ||
| Q2 25 | $18.7M | $18.9M | ||
| Q1 25 | $50.9M | $14.9M | ||
| Q4 24 | $38.1M | $18.2M | ||
| Q3 24 | $33.4M | $25.6M | ||
| Q2 24 | $25.1M | $35.4M | ||
| Q1 24 | $41.5M | $30.2M |
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | $-154.0K | $77.7K | ||
| Q1 25 | $23.5M | $-2.1M | ||
| Q4 24 | $18.9M | $-1.7M | ||
| Q3 24 | $5.7M | $-2.5M | ||
| Q2 24 | $-6.5M | $2.8M | ||
| Q1 24 | $13.8M | $3.2M |
| Q4 25 | — | 41.5% | ||
| Q3 25 | — | 42.0% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 28.4% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 27.2% | ||
| Q2 24 | — | 32.5% | ||
| Q1 24 | — | 34.7% |
| Q4 25 | — | 13.1% | ||
| Q3 25 | — | 10.5% | ||
| Q2 25 | -6.9% | 0.8% | ||
| Q1 25 | 44.4% | -18.2% | ||
| Q4 24 | 46.4% | -15.4% | ||
| Q3 24 | 12.3% | 1.2% | ||
| Q2 24 | -33.7% | 10.1% | ||
| Q1 24 | 28.1% | 13.2% |
| Q4 25 | — | 9.5% | ||
| Q3 25 | — | 9.0% | ||
| Q2 25 | -0.8% | 0.4% | ||
| Q1 25 | 46.2% | -14.0% | ||
| Q4 24 | 49.6% | -9.5% | ||
| Q3 24 | 17.2% | -9.8% | ||
| Q2 24 | -26.0% | 8.0% | ||
| Q1 24 | 33.3% | 10.6% |
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.04 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $-0.05 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $0.07 | ||
| Q1 24 | — | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $5.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $23.7M |
| Total Assets | $175.1M | $51.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.8M | ||
| Q3 25 | — | $2.6M | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | $3.0M | ||
| Q4 24 | $38.1M | $10.2M | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $23.7M | ||
| Q3 25 | — | $21.7M | ||
| Q2 25 | $119.9M | $20.2M | ||
| Q1 25 | $25.0M | $19.9M | ||
| Q4 24 | $-456.0K | $21.7M | ||
| Q3 24 | $-23.5M | $22.5M | ||
| Q2 24 | $-31.2M | $24.7M | ||
| Q1 24 | $-31.7M | $18.1M |
| Q4 25 | — | $51.4M | ||
| Q3 25 | — | $44.4M | ||
| Q2 25 | $175.1M | $45.9M | ||
| Q1 25 | $98.5M | $46.4M | ||
| Q4 24 | $120.5M | $54.9M | ||
| Q3 24 | $139.0M | $57.1M | ||
| Q2 24 | $159.2M | $49.9M | ||
| Q1 24 | $184.7M | $47.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $4.0M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 2.01× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.0M | ||
| Q3 25 | — | $633.2K | ||
| Q2 25 | $-15.8M | $-1.4M | ||
| Q1 25 | $-21.0M | $-3.3M | ||
| Q4 24 | $-19.9M | $9.1M | ||
| Q3 24 | $-20.7M | $4.7M | ||
| Q2 24 | $-19.5M | $-6.5M | ||
| Q1 24 | $-26.0M | $-637.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | $9.0M | ||
| Q3 24 | $-20.7M | $4.6M | ||
| Q2 24 | $-19.6M | $-6.7M | ||
| Q1 24 | $-26.2M | $-741.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | 49.7% | ||
| Q3 24 | -62.1% | 18.1% | ||
| Q2 24 | -78.2% | -19.0% | ||
| Q1 24 | -63.1% | -2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | 0.2% | ||
| Q3 24 | 0.1% | 0.3% | ||
| Q2 24 | 0.4% | 0.7% | ||
| Q1 24 | 0.3% | 0.3% |
| Q4 25 | — | 2.01× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | -17.92× | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | -2.30× | ||
| Q1 24 | -1.89× | -0.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
MAMO
Segment breakdown not available.
